Association between hereditary hemochromatosis and hepatocellular carcinoma: a comprehensive review […]Read More… from Association between hereditary hemochromatosis and hepatocellular carcinoma: a comprehensive review
In vivo quantitative visualization of hypochlorous acid in the liver using a novel selective two-photon fluorescent probe […]Read More… from In vivo quantitative visualization of hypochlorous acid in the liver using a novel selective two-photon fluorescent probe
Characterizing and combating the immune modulatory and epithelial-to-mesenchymal plasticity properties of hepatocellular carcinoma-derived cancer stem cells […]Read More… from Characterizing and combating the immune modulatory and epithelial-to-mesenchymal plasticity properties of hepatocellular carcinoma-derived cancer stem cells
Evaluation of tumor specific promoters for transcriptional targeting of hepatocellular carcinoma […]Read More… from Evaluation of tumor specific promoters for transcriptional targeting of hepatocellular carcinoma
Prognostic Impact of Immune Checkpoint Inhibitor Expression and Its Association with Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma […]Read More… from Prognostic Impact of Immune Checkpoint Inhibitor Expression and Its Association with Epithelial-to-Mesenchymal Transition in Hepatocellular Carcinoma
Necroptosis Contributes to Cell Death of Steatotic Hepatocytes Following Ischaemic Injury […]Read More… from Necroptosis Contributes to Cell Death of Steatotic Hepatocytes Following Ischaemic Injury
Attenuation of receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) blocks the TRIF-RIPK3-MLKL-driven necroptotic cell death in steatotic hepatocytes undergoing ischemic injury […]Read More… from Attenuation of receptor-interacting protein kinase 3 (RIPK3) and mixed lineage kinase domain like pseudokinase (MLKL) blocks the TRIF-RIPK3-MLKL-driven necroptotic cell death in steatotic hepatocytes undergoing ischemic injury
Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma […]Read More… from Immune checkpoint inhibitors and tumor mutation burden as predictive biomarkers in hepatocellular carcinoma
Exosome-based liquid biopsy in the management of hepatocellular carcinoma […]Read More… from Exosome-based liquid biopsy in the management of hepatocellular carcinoma
Immune checkpoint blockade therapies for HCC: current status and future implications […]Read More… from Immune checkpoint blockade therapies for HCC: current status and future implications
TNF-α promotes epithelial-to-mesenchymal transition and expression of immune checkpoint molecules in hepatocellular carcinoma […]Read More… from TNF-α promotes epithelial-to-mesenchymal transition and expression of immune checkpoint molecules in hepatocellular carcinoma
Combination targeting of epithelial-to-mesenchymal transition and immune checkpoint molecules resensitizes hepatocellular carcinoma to sorafenib treatment […]Read More… from Combination targeting of epithelial-to-mesenchymal transition and immune checkpoint molecules resensitizes hepatocellular carcinoma to sorafenib treatment
Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF? […]Read More… from Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF?
Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells […]Read More… from Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma. […]Read More… from Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma. […]Read More… from Epithelial-to-Mesenchymal Transition: A Mediator of Sorafenib Resistance in Advanced Hepatocellular Carcinoma.
Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity. […]Read More… from Murine hepatocellular carcinoma derived stem cells reveal epithelial-to-mesenchymal plasticity.
Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma. […]Read More… from Seek and destroy: targeted adeno-associated viruses for gene delivery to hepatocellular carcinoma.
Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma. […]Read More… from Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma.
Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma. […]Read More… from Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma.
Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma. […]Read More… from Spotlight on Bortezomib: potential in the treatment of hepatocellular carcinoma.
TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma. […]Read More… from TNF‑α‑mediated epithelial‑to‑mesenchymal transition regulates expression of immune checkpoint molecules in hepatocellular carcinoma.
Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma. […]Read More… from Immune checkpoint molecules are regulated by transforming growth factor (TGF)-β1-induced epithelial-to-mesenchymal transition in hepatocellular carcinoma.
Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to Sorafenib treatment. […]Read More… from Combined inhibition of TGF-β1-induced EMT and PD-L1 silencing re-sensitizes hepatocellular carcinoma to Sorafenib treatment.
Liver CancerLiver Cancer
Liver Cancer